FDA Approved: KISQALI FEMARA CO-PACK — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for a Kisqali-Femara co-pack, combining ribociclib and letrozole in a single co-pack managed by Novartis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• FEMARA (letrozole)
• KISQALI (ribociclib)

Snippet

SUPPL AP for KISQALI FEMARA CO-PACK (LETROZOLE AND RIBOCICLIB)